株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

HER-2陽性乳癌の世界市場:2015-2019年

Global HER-2 Positive Breast Cancer Market 2015-2019

発行 TechNavio (Infiniti Research Ltd.) 商品コード 325503
出版日 ページ情報 英文 123 Pages
即納可能
価格
本日の銀行送金レート: 1USD=115.27円で換算しております。
Back to Top
HER-2陽性乳癌の世界市場:2015-2019年 Global HER-2 Positive Breast Cancer Market 2015-2019
出版日: 2015年03月04日 ページ情報: 英文 123 Pages
概要

GLOBOCANの報告によれば、2012年の乳癌患者数は癌患者数全体の11.9%を占め、死亡数は世界で522,000件にのぼりました。HER-2陽性乳癌は乳癌患者数全体の約25%を占めています。2014年から2019年にかけて、世界のHER-2陽性乳癌の市場は9.90%のCAGRで成長すると予測されています。

当レポートでは、HER-2陽性乳癌の治療に用いられる薬剤の市場について調査し、HER-2陽性乳癌の概要、診断法・疾病管理・治療法の種類と概要、パイプラインの動向、治療法および薬剤タイプ・分子タイプ・投与経路・地域別の市場規模の推移と予測、市場成長への各種影響因子の分析、主な薬剤の評価、競合環境および市場シェア、主要事業者のプロファイルなどをまとめています。

第1章 エグゼクティブサマリー

第2章 略語リスト

第3章 調査範囲

  • 市場概要
  • 主な製品

第4章 市場調査手法

  • 市場調査プロセス
  • 調査手法

第5章 イントロダクション

第6章 疾患の概要

  • 疾患について
  • 病態生理
  • 疾学
  • 診断
    • 免疫組織化学検査
    • FISH法
    • SPoT-Light HER2 CISH検査 (Subtraction Probe Technology Chromogenic In Situ Hybridization検査)
    • Inform HER2 Dual ISH検査 (Inform Dual In Situ Hybridization検査)
  • 疾病管理
    • 手術
    • 放射線治療
    • 化学療法
    • 標的治療
    • ホルモン療法
  • 経済的負担

第7章 パイプライン分析

第8章 市場環境

  • 市場概要
  • 市場規模・予測
  • HER-2陽性乳癌市場:米国
    • 市場規模・予測
  • HER-2陽性乳癌市場:EU
    • 市場規模・予測
  • ファイブフォース分析

第9章 治療・薬剤タイプ別市場

  • 化学療法
    • アルキル化薬
    • 代謝拮抗薬
    • 細胞毒性抗生物質
    • タキサン類
  • 標的治療
  • ホルモン療法

第10章 分子タイプ別市場

  • 生物学的製剤
  • 小分子

第11章 投与経路別市場

  • 経口
  • 非経口

第12章 地域別市場

第13章 購入基準

第14章 市場成長促進要因

第15章 成長促進要因とその影響

第16章 市場の課題

第17章 成長促進要因と課題の影響

第18章 市場動向

第19章 動向とその影響

第20章 ベンダー情勢

  • 競合シナリオ
    • 主要ニュース
    • M&A
  • 市場シェア分析
    • 主要薬剤の競合評価
    • Celgene
    • F. Hoffmann-La Roche
    • GlaxoSmithKline
    • Novartis
    • Sanofi
  • 標的治療のSWOT分析
    • ハーセプチン
    • カドサイラ
    • パージェタ
    • タイケルブ
  • その他の主要ベンダー

第21章 主要ベンダーの分析

  • Celgene
  • F. Hoffmann-La Roche
  • GlaxoSmithKline
  • Novartis
  • Sanofi
    • 主要データ
    • 事業概要
    • 部門別の市場収益
    • 地域別の市場収益
    • 事業戦略
    • 最近の発展動向
    • SWOT分析、など

第22章 関連レポート

図表

目次
Product Code: IRTNTR5462

About HER-2 Positive Breast Cancer

Breast cancer is characterized by uncontrolled growth of cancerous cells in the breast. It occurs in both males and females, however, the incidence of breast cancer in males is rare. Histologically, breast cancer can be classified into ductal carcinoma, lobular carcinoma, nipple cancer, and other undifferentiated carcinoma. Breast cancer is the second most common form of cancer in women. HER-2 is a protein that affects the growth of malignant cells and is usually found on the surface of normal breast cells. Sometimes, a large number of HER-2 receptors are found on the surface of breast cancer cells. These HER-2 receptors are responsible for stimulating the growth and division of malignant cancerous cells. This condition is therefore known as HER-2 positive breast cancer. HER-2 positive breast cancers have a tendency to spread and metastasize more rapidly than HER-2 negative breast cancers. HER-2 positive breast cancer is more prevalent in females than males. In 2012, GLOBOCAN reported that breast cancer accounted for 11.9

percent of the total number of cancer cases and led to 522,000 deaths worldwide. HER-2 positive breast cancer accounts for almost 25 percent of all types of breast cancer.

TechNavio's analysts forecast the Global HER-2 Positive Breast Cancer market to grow at a CAGR of 9.90 percent over the period 2014-2019.

Covered in this Report

This report covers the present scenario and the growth prospects of the Global HER-2 Positive Breast Cancer Market for the period 2015-2019. To calculate the market size, the report considers revenue generated through the sales of targeted therapeutic agents, chemotherapeutic agents, and hormonal therapies that are used in the management of HER-2 positive breast cancer patients.

The report also presents the vendor landscape and a corresponding detailed analysis of the top vendors in the Global HER-2 Positive Breast Cancer market. In addition, it discusses the major drivers that influence the growth of the market. It also outlines the challenges faced by the vendors and the market at large, as well as the key trends that are emerging in the market.

TechNavio's report, Global HER-2 Positive Breast Cancer Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, and the EMEA and APAC regions; it also covers the Global HER-2 Positive Breast Cancer market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key Regions

  • Americas
  • APAC
  • EMEA

Key Vendors

  • Celgene
  • F. Hoffmann-La Roche
  • GlaxoSmithKline
  • Novartis
  • Sanofi

Other Prominent Vendors

  • Actavis
  • Array BioPharma
  • Biocad
  • Biocon
  • Boehringer Ingelheim
  • Bristol-Myers Squibb
  • Celltrion
  • Chugai Pharmaceutical
  • DARA BioSciences
  • EddingPharm
  • Eisai
  • Galena Biopharma
  • Halozyme Therapeutics
  • Hospira
  • Mylan
  • Oncothyreon
  • Pfizer
  • ProStrakan
  • Puma Biotechnology
  • Sun Pharmaceutical Industries
  • Synta Pharmaceuticals
  • Teva Pharmaceutical

Market Driver

  • Increase in Population of Breast Cancer Patients
  • For a full, detailed list, view our report

Market Challenge

  • Poor Diagnosis and Screening
  • For a full, detailed list, view our report

Market Trend

  • Increase in Awareness
  • For a full, detailed list, view our report

Key Questions Answered in this Report

  • What will the market size be in 2019 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?

Table of Contents

01. Executive Summary

02. List of Abbreviations

03. Scope of the Report

  • 03.1. Market Overview
  • 03.2. Product Offerings

04. Market Research Methodology

  • 04.1. Market Research Process
  • 04.2. Research Methodology

05. Introduction

06. Disease Overview

  • 06.1. Understanding the Disease
  • 06.2. Pathophysiology
  • 06.3. Epidemiology
  • 06.4. Diagnosis
    • 06.4.1. Immunohistochemistry
    • 06.4.2. FISH
    • 06.4.3. SPoT-Light HER2 CISH Test (Subtraction Probe Technology Chromogenic In Situ Hybridization)
    • 06.4.4. Inform HER2 Dual ISH Test (Inform Dual In Situ Hybridization)
  • 06.5. Management
    • 06.5.1. Surgery
    • 06.5.2. Radiotherapy
    • 06.5.3. Chemotherapy
    • 06.5.4. Targeted Therapy
    • 06.5.5. Hormonal Therapy
  • 06.6. Economic Burden

07. Pipeline Analysis

08. Market Landscape

  • 08.1. Market Overview
  • 08.2. Market Size and Forecast
  • 08.3. HER-2 Positive Breast Cancer Market in US
    • 08.3.1. Market Size and Forecast
  • 08.4. HER-2 Positive Breast Cancer Market in EU
    • 08.4.1. Market Size and Forecast
  • 08.5. Five Forces Analysis

09. Market Segmentation by Type of Therapy

  • 09.1. Chemotherapy
    • 09.1.1. Alkylating agents
    • 09.1.2. Antimetabolites
    • 09.1.3. Cytotoxic antibiotics
    • 09.1.4. Taxanes
  • 09.2. Targeted Therapy
  • 09.3. Hormone Therapy

10. Market Segmentation by Molecule Type

  • 10.1. Biologics
  • 10.2. Small Molecules

11. Market Segmentation by Route of Administration

  • 11.1. Oral
  • 11.2. Parenteral

12. Geographical Segmentation

13. Buying Criteria

14. Market Growth Drivers

15. Drivers and their Impact

16. Market Challenges

17. Impact of Drivers and Challenges

18. Market Trends

19. Trends and their Impact

20. Vendor Landscape

  • 20.1. Competitive Scenario
    • 20.1.1. Key News
    • 20.1.2. Mergers and Acquisitions
  • 20.2. Market Share Analysis 2014
    • 20.2.1. Competitive Assessment of the Top Drugs
    • 20.2.2. Celgene
    • 20.2.3. F. Hoffmann-La Roche
    • 20.2.4. GlaxoSmithKline
    • 20.2.5. Novartis
    • 20.2.6. Sanofi
  • 20.3. SWOT Analysis of the Targeted Therapies
    • 20.3.1. Herceptin
    • 20.3.2. Kadcyla
    • 20.3.3. Perjeta
    • 20.3.4. Tykerb
  • 20.4. Other Prominent Vendors

21. Key Vendor Analysis

  • 21.1. Celgene
    • 21.1.1. Key Facts
    • 21.1.2. Business Overview
    • 21.1.3. Business Strategy
    • 21.1.4. Business Segmentation by Revenue
    • 21.1.5. Sales by Geography
    • 21.1.6. Key Information
    • 21.1.7. SWOT Analysis
  • 21.2. F. Hoffmann-La Roche
    • 21.2.1. Key Facts
    • 21.2.2. Business Overview
    • 21.2.3. Business Segmentation
    • 21.2.4. Business Segmentation by Revenue 2012 and 2013
    • 21.2.5. Sales by Geography
    • 21.2.6. Business Strategy
    • 21.2.7. Key Information
    • 21.2.8. SWOT Analysis
  • 21.3. GlaxoSmithKline
    • 21.3.1. Key Facts
    • 21.3.2. Business Overview
    • 21.3.3. Business Segmentation
    • 21.3.4. Business Segmentation by Revenue 2012 and 2013
    • 21.3.5. Sales by Geography
    • 21.3.6. Pipeline Products
    • 21.3.7. Business Strategy
    • 21.3.8. Key Information
    • 21.3.9. SWOT Analysis
  • 21.4. Novartis
    • 21.4.1. Key Facts
    • 21.4.2. Business Description
    • 21.4.3. Business Segmentation
    • 21.4.4. Revenue by Business Segmentation
    • 21.4.5. Revenue Comparison 2012 and 2013
    • 21.4.6. Sales by Geography
    • 21.4.7. Business Strategy
    • 21.4.8. Key Developments
    • 21.4.9. SWOT Analysis
  • 21.5. Sanofi
    • 21.5.1. Key Facts
    • 21.5.2. Business Description
    • 21.5.3. Business Segmentation
    • 21.5.4. Revenue by Business Segmentation
    • 21.5.5. Revenue Comparison 2012 and 2013
    • 21.5.6. Sales by Geography
    • 21.5.7. Business Strategy
    • 21.5.8. Key Developments
    • 21.5.9. SWOT Analysis

22. Other Reports in this Series

List of Exhibits

  • Exhibit 1: Market Research Methodology
  • Exhibit 2: Executive Summary of Global HER-2 Positive Breast Cancer Market 2015-2019
  • Exhibit 3: Pathophysiology: HER-2 Positive Breast Cancer
  • Exhibit 4: Prevalence Data of HER-2 Positive Breast Cancer in the US, 2014
  • Exhibit 5: Diagnosis of HER-2 Positive Breast Cancer: IHC
  • Exhibit 6: Diagnosis of HER-2 Positive Breast Cancer: FISH
  • Exhibit 7: Management of HER-2 Positive Breast Cancer
  • Exhibit 8: ASCO Treatment Guidelines: HER-2 Positive Breast Cancer
  • Exhibit 9: Snapshot of Economic Burden of the HER-2 Positive Breast Cancer Market in US
  • Exhibit 10: Pipeline Snapshot: Combination Therapies
  • Exhibit 11: Pipeline Snapshot: Therapeutic Vaccines
  • Exhibit 12: Snapshot of Global HER-2 Positive Breast Cancer Market 2014
  • Exhibit 13: Global HER-2 Positive Breast Cancer Market 2014-2019 (US$ million)
  • Exhibit 14: Drivers and Challenges of the Global HER-2 Positive Breast Cancer Market
  • Exhibit 15: HER-2 Positive Breast Cancer Market in US 2014-2019 (US$ million)
  • Exhibit 16: HER-2 Positive Breast Cancer Market in EU 2014-2019 (US$ million)
  • Exhibit 17: Global HER-2 Positive Breast Cancer Market Segmentation by Type of Therapy
  • Exhibit 18: Global HER-2 Positive Breast Cancer Market Segmentation by Type of Therapy 2014
  • Exhibit 19: Global HER-2 Positive Breast Cancer Market Segmentation by Molecule Type
  • Exhibit 20: Global HER-2 Positive Breast Cancer Market Segmentation by Molecule Type 2014
  • Exhibit 21: Global HER-2 Positive Breast Cancer Market Segmentation by Route of Administration
  • Exhibit 22: Global HER-2 Positive Breast Cancer Market Segmentation by Route of Administration 2014
  • Exhibit 23: Geographical Segmentation of Global HER-2 Positive Breast Cancer Market 2014
  • Exhibit 24: 5-Year Survival Rate by Stage of Diagnosis (SEER analysis for 2004-2010)
  • Exhibit 25: Revenue Comparison of Top Drugs for HER-2 Positive Breast Cancer in 2013 (US$ million)
  • Exhibit 26: Product Portfolio: Celgene
  • Exhibit 27: YoY Growth Rate and Global Revenue of Abraxane 2010-2013 (US$ million)
  • Exhibit 28: Product Portfolio: F. Hoffmann-La Roche
  • Exhibit 29: YoY Growth Rate and Revenue of Herceptin 2010-2013 (US$ million)
  • Exhibit 30: Revenue of Perjeta for 2012-2013 (US$ million)
  • Exhibit 31: YoY Growth Rate and Revenue of Xeloda 2010-2013 (US$ million)
  • Exhibit 32: Product Portfolio: GlaxoSmithKline
  • Exhibit 33: YoY Growth Rate and Revenue of Tykerb 2010-2013 (US$ million)
  • Exhibit 34: Product Portfolio: Novartis
  • Exhibit 35: YoY Growth Rate and Revenue of Femara 2010-2013 (US$ million)
  • Exhibit 36: Product Portfolio: Sanofi
  • Exhibit 37: YoY Growth Rate and Global Revenue of Taxotere 2010-2013 (US$ million)
  • Exhibit 38: Herceptin: SWOT Analysis
  • Exhibit 39: Kadcyla: SWOT Analysis
  • Exhibit 40: Perjeta: SWOT Analysis
  • Exhibit 41: Tykerb: SWOT Analysis
  • Exhibit 42: Celgene: Business Segmentation by Revenue 2011-2013 (US$ million)
  • Exhibit 43: Celgene: Sales by Geography 2013
  • Exhibit 44: Business Segmentation of F. Hoffmann-La Roche Ltd. 2013
  • Exhibit 45: F. Hoffmann-La Roche Ltd.: Business Segmentation by Revenue 2012 and 2013
  • Exhibit 46: F. Hoffmann-La Roche Ltd.: Sales by Geography 2013 (Pharmaceuticals Division)
  • Exhibit 47: F. Hoffmann-La Roche Ltd.: Sales by Geography 2013 (Diagnostics Division)
  • Exhibit 48: GlaxoSmithKline: Business Segmentation 2013
  • Exhibit 49: GlaxoSmithKline: Business Segmentation by Revenue 2012 and 2013 (US$ billion)
  • Exhibit 50: GlaxoSmithKline: Sales by Geography 2013
  • Exhibit 51: GlaxoSmithKline: Pipeline Products 2013
  • Exhibit 52: Novartis AG: Business Segmentation
  • Exhibit 53: Novartis AG: Revenue by Business Segmentation 2013
  • Exhibit 54: Novartis AG: Revenue by Business Segmentation 2012 and 2013 (US$ million)
  • Exhibit 55: Novartis AG: Revenue by Geographical Segmentation 2013
  • Exhibit 56: Sanofi SA: Business Segmentation
  • Exhibit 57: Sanofi SA: Revenue by Business Segmentation 2013
  • Exhibit 58: Sanofi SA: Revenue by Business Segmentation 2012 and 2013 (US$ million)
  • Exhibit 59: Sanofi SA: Sales Revenue by Geographical Segmentation 2013
Back to Top